Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Johnson & Johnson Partner Contineum Slides as Depression Drug Fails Trial

Guavy AI Editorial Team
Instruments
JNJ
Share

Contineum Therapeutics' shares are trading lower on Tuesday due to disappointing Phase 2 results from its key MOONLIGHT-1 trial.

The study did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder, a condition being developed by Johnson & Johnson under a global license and development agreement.

JNJ-5120/PIPE-307 is still being evaluated by Johnson & Johnson, which will assess the trial data to determine next steps.

More on Stocks

Stocks 6m ago

US Stocks Plummet as Oil Prices, Treasury Yields Pressure Market

Stocks 7m ago

Apple Stock Falls as Investors Assess iPhone Demand and AI-Powered Siri

Stocks 7m ago

iPhone Delays Hit as Strong Demand Takes Its Toll on Apple's Latest Releases

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy